Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death

Summary

This is a multi-center, randomized controlled, superiority, open label trial. The objective of this trial is to evaluate the efficacy of HCQ in patients with newly diagnosed COVID-19 who have mild to moderate disease or at risk for complications. We aim to demonstrate decrease in progression to severe pneumonia and hospital related complications among patients who are treated with HCQ compared to patients who are not.

Timeline

Start

2020-04-30

Primary completion

2020-04-30

Completion

2020-04-30

Outcome

Outcome not reported

Stopped: “Trial not started due to accumulating evidence against HCQ for COVID”

Drugs

Indications